MEMPHASYS LTD (IG7) - Total Liabilities
Based on the latest financial reports, MEMPHASYS LTD (IG7) has total liabilities worth €5.59 Million EUR (≈ $6.54 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of MEMPHASYS LTD to track the company's year-over-year net asset growth rate.
MEMPHASYS LTD - Total Liabilities Trend (2021–2024)
This chart illustrates how MEMPHASYS LTD's total liabilities have evolved over time, based on quarterly financial data.
MEMPHASYS LTD Competitors by Total Liabilities
The table below lists competitors of MEMPHASYS LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NewRiver REIT plc
LSE:NRR
|
UK | GBX565.80 Million |
|
Brüder Mannesmann Aktiengesellschaft
F:BMM
|
Germany | €49.16 Million |
|
Benjamin Hornigold Ltd
AU:BHD
|
Australia | AU$616.06K |
|
Accord Financial Corp.
TO:ACD
|
Canada | CA$140.57 Million |
|
Tartana Minerals Ltd
AU:TAT
|
Australia | AU$7.54 Million |
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
USA | $53.05 Million |
|
Winshear Gold Corp
V:WINS
|
Canada | CA$71.01K |
|
Alliance Pharma plc
LSE:APH
|
UK | GBX161.50 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down MEMPHASYS LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of MEMPHASYS LTD.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MEMPHASYS LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MEMPHASYS LTD (2021–2024)
The table below shows the annual total liabilities of MEMPHASYS LTD from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €5.59 Million ≈ $6.54 Million |
-23.21% |
| 2023-06-30 | €7.28 Million ≈ $8.51 Million |
+12.49% |
| 2022-06-30 | €6.47 Million ≈ $7.57 Million |
+8.38% |
| 2021-06-30 | €5.97 Million ≈ $6.98 Million |
-- |
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more